Pàgina inicial > Resultats de la cerca: Kobos, R.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
8 p, 1.0 MB Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma / Moreau, Philippe (University Hospital Hôtel-Dieu) ; Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ; Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K (Winship Cancer Institute. Emory University) ; Martin, Thomas (University of California San Francisco) ; Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ; Karlin, Lionel (Centre Hospitalier Lyon Sud) ; Benboubker, Lotfi (Hôpital Bretonneau) ; Mateos, Maria-Victoria (University Hospital de Salamanca) ; Popat, Rakesh (University College London Hospitals) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Sidana, Surbhi (Stanford University of Medicine) ; Delforge, Michele (University of Leuven) ; Pei, Lixia (Janssen Research & Development) ; Trancucci, Danielle (Janssen Research & Development) ; Olyslager, Yunsi (Janssen Research & Development) ; Uhlar, Clarissa (Janssen Research & Development) ; Stephenson, Tara (Janssen Research & Development) ; Rampelbergh, Rian Van (Janssen Research & Development) ; Banerjee, Arnob (Janssen Research & Development) ; Kobos, Rachel (Janssen Research & Development) ; Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818  
Registre complet - Creative Commons
2.
9 p, 603.3 KB Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study / Martin, Thomas G. (University of California San Francisco, USA) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ; Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ; Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ; Mateos, M. V (Hospital Universitario de Salamanca) ; San-Miguel, Jesús F. (Clínica Universidad de Navarra) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K. (Emory University, Atlanta, GA) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ; Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ; Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Bahlis, Nizar (University of Calgary, Canada) ; Popat, Rakesh (University College London) ; Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ; Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ; Pei, Lixia (Janssen Research & Development, Raritan, NJ) ; Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ; Fastenau, John (Janssen Research & Development, Raritan, NJ) ; Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ; van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023  
Registre complet - Creative Commons
3.
10 p, 667.7 KB Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX / Kaufman, J. L. (Winship Cancer Institute. Emory University) ; Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ; White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire) ; Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds) ; Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev) ; Morton, J. (Icon Cancer Care) ; Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital) ; Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan) ; Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu) ; Sutherland, H. J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia) ; Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences) ; Kim, J. S. (Yonsei University College of Medicine. Severance Hospital) ; Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Cochrane, T. (Gold Coast University Hospital and Griffiths University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bahlis, N. J. (University of Calgary. Arnie Charbonneau Cancer Institute) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai) ; O'Rourke, L. (Janssen Research & Development) ; Trivedi, S. (Janssen Research & Development) ; Casneuf, T. (Janssen Research & Development) ; Krevvata, M. (Janssen Research & Development) ; Ukropec, J. (Janssen Global Medical Affairs) ; Kobos, R. (Janssen Research & Development) ; Avet-Loiseau, Hervé (Unite de Genomique du Myelome. IUC-Oncopole) ; Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ; San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
2 Kobos, Rachel
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem